|
The first three articles that appear in this issue make up a series of stories about modifications to the ECOG-ACRIN biorepository and pathology capabilities.
ECOG-ACRIN Opens Central Biorepository and Pathology Facility at MD Anderson Cancer Center
The ECOG-ACRIN Cancer Research Group has begun important modifications to its biorepositories and pathology capabilities, which includes consolidating the majority of its banking activities into the new ECOG-ACRIN Central Biorepository and Pathology Facility (EA-CBPF) at The University of Texas MD Anderson Cancer Center in Houston, TX. The new location opened on November 3, 2014. This article introduces readers to Director Ignacio I. Wistuba, MD, Co-Director Stanley R. Hamilton, MD, and their staff. The ECOG-ACRIN Leukemia Tissue Bank remains at the Montefiore Medical Center in Bronx, NY, under the direction of Elisabeth Paietta, PhD.
|
How the New Central Biorepository and Pathology Facility Fits into the Overall Group Organizational Structure
This article describes how ECOG-ACRIN Headquarters and the Laboratory Science and Pathology Committee oversee the new ECOG-ACRIN Central Biorepository and Pathology Facility and its interactions with operations, biostatistics, and the scientific committees. A downloadable organizational chart illustrates the scientific structure, including the disease site committees served and materials routinely collected.
|
|
Central Biorepository Transition Plan Details Released
The opening of the ECOG-ACRIN Central Biorepository and Pathology Facility on November 3, 2014, was the first major milestone in a five-year transition of the existing biorepositories. This article explains the funding, transition logistical planning and schedule, and details about specimen shipments.
|
|
E2112 Trial Spotlight
We recently conducted a Q&A with Roisin M. Connolly, MB, BCh, study chair for E2112, a new trial that activated on March 19, 2014. Finding drugs that improve the efficacy of endocrine therapy in breast cancer is an important clinical need. In E2112, a randomized, phase III trial, the ECOG-ACRIN Breast Cancer Committee seeks to improve on the efficacy of an aromatase inhibitor (exemestane) in patients with advanced breast cancer and elucidate the role of entinostat, a histone deacetylase (HDAC) inhibitor.
|
Eight Young Investigators to Present Diverse Research
The selection committee for the ECOG-ACRIN Young Investigator Symposium named eight young investigators to orally present their research at the 14th annual event, taking place during the upcoming ECOG-ACRIN Fall 2014 Group Meeting in Orlando, FL. The committee made the selections after reviewing 23 abstracts submitted this year. Criteria used to judge the abstracts include scientific innovation, significance, and ultimate potential for clinical impact.
|
|
|
|
|
|
|
|
|
|
Latest Group Meeting Information
The Fall 2014 Group Meeting takes place this week, from Thursday morning, November 13 through Saturday afternoon, November 15, 2014, in Orlando, FL at the JW Marriott and The Ritz-Carlton Orlando Grande Lakes.
Watch for meeting highlights in a future newsletter.
The ECOG-ACRIN Spring 2015 Group Meeting will be held Thursday morning, April 30 through Saturday afternoon, May 2, 2015.
The dates for this meeting are confirmed; however, the exact start and end times are to be determined.
JW Marriott Chicago
151 West Adams Street
Chicago, IL 60603
Phone: 312.660.8200
|
|
Now Posted: Revised ECOG-ACRIN Roster Update Form
The ECOG-ACRIN roster update form has been modified. Please use the modified form to submit requests for listings of new research personnel or to update existing listings.
The form now features an interactive "Submit via Email" button for your convenience.
|
Have a suggestion for a future newsletter topic?
|
|
